Impact of body mass index on long-term clinical outcomes after second-generation drug eluting stent implantation: Insights from the international global RESOLUTE program

Catheterization and Cardiovascular Interventions

Volumn 85, Issue 6, 2015, Pages 952-958

  Diletti, Roberto ^a   Garcia Garcia, Hector M ^a,b   Bourantas, Christos ^a   Van Mieghem, Nicolas M ^a   Van Geuns, Robert Jan ^a   Muramatsu, Takashi ^a   Zhang, Yao Jun ^a   Mauri, Laura ^c   Belardi, Jorge ^d   Silber, Sigmund ^e   Widimsky, Petr ^f   Leon, Martin ^g   Windecker, Stephan ^h   Meredith, Ian ⁱ   Neumann, Franz Josef ^j   Yeung, Alan C ^k   Saito, Shigeru ^l   Liu, Minglei ^m   Van Leeuwen, Frank ^m   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CARDIALYSIS   (Netherlands)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d INSTITUTO CARDIOVASCULAR DE BUENOS AIRES   (Argentina)

^e Heart Center at the Isar   (Germany)

^f CHARLES UNIVERSITY   (Czech Republic)

^g Department of Medicine   (United States)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ MONASH UNIVERSITY   (Australia)

^j UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

^m MEDTRONIC INC   (United States)

more..

Author keywords

coronary artery disease; obesity paradox; zotarolimus eluting stents

Indexed keywords

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DRUG ELUTING CORONARY STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART DISEASE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; PROGNOSIS; REPEAT PROCEDURE; STENT THROMBOSIS; ZOTAROLIMUS ELUTING CORONARY STENT; AGED; ANGIOCARDIOGRAPHY; CLINICAL TRIAL; COHORT ANALYSIS; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG ELUTING STENT; FACTUAL DATABASE; INTERNATIONAL COOPERATION; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EVEROLIMUS;

AGED; ANGIOPLASTY, BALLOON, CORONARY; BODY MASS INDEX; COHORT STUDIES; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; DATABASES, FACTUAL; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONALITY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928609723     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.25828     Document Type: Article

References (39)

1. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB,. Overweight and obesity as determinants of cardiovascular risk: The Framingham experience. Arch Intern Med 2002; 162: 1867-1872.
2. Hubert HB, Feinleib M, McNamara PM, Castelli WP,. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham heart study. Circulation 1983; 67: 968-977.
3. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS,. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305-313.
4. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW,J,. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341: 1097-1105.
5. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB,. Years of life lost due to obesity. JAMA 2003; 289: 187-193.
6. Galal W, van Gestel YR, Hoeks SE, Sin DD, Winkel TA, Bax JJ, Verhagen H, Awara AM, Klein J, van Domburg RT, et al. The obesity paradox in patients with peripheral arterial disease. Chest 2008; 134: 925-930.
7. Uretsky S, Messerli FH, Bangalore S, Champion A, Cooper-Dehoff RM, Zhou Q, Pepine CJ,. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med 2007; 120: 863-870.
8. Curtis JP, Selter JG, Wang Y, Rathore SS, Jovin IS, Jadbabaie F, Kosiborod M, Portnay EL, Sokol SI, Bader F, et al. The obesity paradox: Body mass index and outcomes in patients with heart failure. Arch Intern Med 2005; 165: 55-61.
9. Lancefield T, Clark DJ, Andrianopoulos N, Brennan AL, Reid CM, Johns J, Freeman M, Charter K, Duffy SJ, Ajani AE, et al. Is there an obesity paradox after percutaneous coronary intervention in the contemporary era? An analysis from a multicenter Australian registry. JACC Cardiovasc Interv 2010; 3: 660-668.
10. Dorresteijn JA, Visseren FL, Spiering W,. Mechanisms linking obesity to hypertension. Obes Rev 2012; 13: 17-26.
11. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM,. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45: 356-362.
12. Johnson WD, Brashear MM, Gupta AK, Rood JC, Ryan DH,. Incremental weight loss improves cardiometabolic risk in extremely obese adults. Am J Med 2011; 124: 931-938.
13. Eilat-Adar S, Eldar M, Goldbourt U,. Association of intentional changes in body weight with coronary heart disease event rates in overweight subjects who have an additional coronary risk factor. Am J Epidemiol 2005; 161: 352-358.
14. Lavie CJ, Morshedi-Meibodi A, Milani RV,. Impact of cardiac rehabilitation on coronary risk factors, inflammation, and the metabolic syndrome in obese coronary patients. J Cardiometab Syndr 2008; 3: 136-140.
15. Lavie CJ, Milani RV, Ventura HO,. Obesity and cardiovascular disease: Risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009; 53: 1925-1932.
16. Lavie CJ, Milani RV, Artham SM, Patel DA, Ventura HO,. The obesity paradox, weight loss, and coronary disease. Am J Med 2009; 122: 1106-1114.
17. Steinberg BA, Cannon CP, Hernandez AF, Pan W, Peterson ED, Fonarow GC,. Medical therapies and invasive treatments for coronary artery disease by body mass: The "obesity paradox" in the get with the guidelines database. Am J Cardiol 2007; 100: 1331-1335.
18. Sibbing D, von Beckerath O, Schomig A, Kastrati A, von Beckerath N,. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am J Cardiol 2007; 100: 203-205.
19. Tamminen M, Lassila R, Westerbacka J, Vehkavaara S, Yki-Jarvinen H,. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord 2003; 27: 907-911.
20. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D,. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317.
21. Wang ZJ, Zhou YJ, Liu YY, Yu M, Shi DM, Zhao YX, Guo YH, Cheng WJ, Nie B, Ge HL, et al. Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents. Heart 2009; 95: 1587-1592.
22. Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, McTiernan C,. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000; 35: 537-544.
23. Meredith IT, Worthley S, Whitbourn R, Walters DL, McClean D, Horrigan M, Popma JJ, Cutlip DE, DePaoli A, Negoita M, et al. Clinical and angiographic results with the next-generation resolute stent system: A prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv 2009; 2: 977-985. [CrossRef][10.1016/j.jcin.2009.07.007]
24. Mauri L, Massaro JM, Jiang S, Meredith I, Wijns W, Fajadet J, Kandzari DE, Leon MB, Cutlip DE, Thompson KP,. Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents. JACC Cardiovasc Interv 2010; 3: 1240-1249.
25. Das SR, Alexander KP, Chen AY, Powell-Wiley TM, Diercks DB, Peterson ED, Roe MT, de Lemos JA,. Impact of body weight and extreme obesity on the presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-segment elevation myocardial infarction results from the NCDR (national cardiovascular data registry). J Am Coll Cardiol 2011; 58: 2642-2650.
26. Hastie CE, Padmanabhan S, Slack R, Pell AC, Oldroyd KG, Flapan AD, Jennings KP, Irving J, Eteiba H, Dominiczak AF, et al. Obesity paradox in a cohort of 4880 consecutive patients undergoing percutaneous coronary intervention. Eur Heart J 2010; 31: 222-226.
27. Schenkeveld L, Magro M, Oemrawsingh RM, Lenzen M, de Jaegere P, van Geuns RJ, Serruys PW, van Domburg RT,. The influence of optimal medical treatment on the 'obesity paradox', body mass index and long-term mortality in patients treated with percutaneous coronary intervention: A prospective cohort study. BMJ Open 2012; 2: e000535.
28. Akin I, Tolg R, Hochadel M, Bergmann MW, Khattab AA, Schneider S, Senges J, Kuck KH, Richardt G, Nienaber CA, et al. No evidence of "obesity paradox" after treatment with drug-eluting stents in a routine clinical practice: Results from the prospective multicenter German DES.DE (German Drug-Eluting Stent) Registry. JACC Cardiovasc Interv 2012; 5: 162-169.
29. Sarno G, Raber L, Onuma Y, Garg S, Brugaletta S, van Domburg RT, Pilgrim T, Pfaffli N, Wenaweser P, Windecker S, et al. Impact of body mass index on the five-year outcome of patients having percutaneous coronary interventions with drug-eluting stents. Am J Cardiol 2011; 108: 195-201.
30. Rubinshtein R, Halon DA, Jaffe R, Shahla J, Lewis BS,. Relation between obesity and severity of coronary artery disease in patients undergoing coronary angiography. Am J Cardiol 2006; 97: 1277-1280.
31. Andreotti F, Rio T, Lavorgna A,. Body fat and cardiovascular risk: Understanding the obesity paradox. Eur Heart J 2009; 30: 752-754.
32. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503-1516.
33. Lavie CJ, Mehra MR, Milani RV,. Obesity and heart failure prognosis: Paradox or reverse epidemiology? Eur Heart J 2005; 26: 5-7.
34. Martin-Ponce E, Santolaria F, Aleman-Valls MR, Gonzalez-Reimers E, Martinez-Riera A, Rodriguez-Gaspar M, Rodriguez-Rodriguez E,. Factors involved in the paradox of reverse epidemiology. Clin Nutr 2010; 29: 501-506.
35. Gruberg L, Weissman NJ, Waksman R, Fuchs S, Deible R, Pinnow EE, Ahmed LM, Kent KM, Pichard AD, Suddath WO, et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: The obesity paradox? J Am Coll Cardiol 2002; 39: 578-584.
36. Zamboni M, Mazzali G, Zoico E, Harris TB, Meigs JB, Di Francesco V, Fantin F, Bissoli L, Bosello O,. Health consequences of obesity in the elderly: A review of four unresolved questions. Int J Obes (Lond) 2005; 29: 1011-1029.
37. Sorkin JD, Muller DC, Andres R,. Longitudinal change in height of men and women: Implications for interpretation of the body mass index: The Baltimore longitudinal study of aging. Am J Epidemiol 1999; 150: 969-977.
38. Hughes VA, Frontera WR, Roubenoff R, Evans WJ, Singh MA,. Longitudinal changes in body composition in older men and women: Role of body weight change and physical activity. Am J Clin Nutr 2002; 76: 473-481.
39. Strandberg TE, Strandberg AY, Salomaa VV, Pitkala KH, Tilvis RS, Sirola J, Miettinen TA,. Explaining the obesity paradox: Cardiovascular risk, weight change, and mortality during long-term follow-up in men. Eur Heart J 2009; 30: 1720-1727.